Table 2.
KEGG Signaling pathways enrichment of SDEGs up regulated in Poly-PN and PN arrest groups separately compared with controls.
| Items | Count | % | P-Value | Genes | |
|---|---|---|---|---|---|
| SDEGs (Poly-PN/Control) | Ribosome | 12 | 5.5 | 5.80E-09 | RPSA, RPL23, RPL9, RPL35, RPL3, RPS9, RPL7A, RPS11, RPS20, RPS4X, RPS8, RPS24 |
| Huntington’s disease | 8 | 3.6 | 6.40E-03 | POLR2F, TAF4, EP300, NDUFB8, NDUFA6, CREBBP, UQCRQ, ATP5J | |
| Wnt signaling pathway | 7 | 3.2 | 1.00E-02 | PRKCA, CTBP1, TCF7, EP300, CREBBP, FRAT1, FRAT2 | |
| Pathway in cancer | 10 | 4.5 | 1.90E-02 | PRKCA, CTBP1, TCF7, EP300, RALBP1, CREBBP, FOXO1, LAMC1, IKBKB, LAMB1 | |
| Spliceosome | 6 | 2.7 | 1.90E-02 | CHERP, PCBP1, LSM7, SNRPD2, SNRPG, SF3B2 | |
| Notch signaling pathway | 4 | 1.8 | 2.00E-02 | CTBP1, EP300, PSEN2, CREBBP | |
| Prostate cancer | 5 | 2.3 | 2.40E-02 | TCF7, EP300, CREBBP, FOXO1, IKBKB | |
| SDEGs (PN arrest/Control) | Ribosome | 56 | 28.1 | 1.10E-84 | RPL36A, RPL19, RPL13, RPLP2, RPS2, RPS3, RPS3A, RPLP0, RPLP1, RPL10, RPL12, RPS27A, RPS4X, RPS18, RPS19, RPL41, RPS16, RPS17, RPS15, RPS12, RPS13, RPS11, UBA52, RPL35, RPS15A, RPL36, RPL37, RPL38, RPS25, RPL30, RPS27, RPS28, RPL32, RPS29, RPL31, RPL8, RPL3, RPL10A, RPL7A, RPL4, RPS20, RPS21, RPS23, RPS24, RPL26, RPS9, RPL27, RPL23A, RPL24, RPS5, RPL28, RPL29, RPL23, RPL13A, RPL37A |
| Oxidative phosphorylation | 11 | 5.5 | 5.20E-05 | ATP5D, NDUFA2, NDUFB10, NDUFB8, NDUFB9, NDUFA6, COX6A1, ATP5L, COX6C, NDUFA11, NDUFB2 | |
| Parkinson’s disease | 9 | 4.5 | 1.20E-03 | ATP5D, NDUFA2, NDUFB10, NDUFB8, NDUFB9, NDUFA6, COX6A1, COX6C, NDUFB2 | |
| Alzheimer’s disease | 9 | 4.5 | 5.50E-03 | ATP5D, NDUFA2, NDUFB10, NDUFB8, NDUFB9, NDUFA6, COX6A1, COX6C, NDUFB2 | |
| Huntington’s disease | 9 | 4.5 | 9.90E-03 | ATP5D, NDUFA2, NDUFB10, NDUFB8, NDUFB9, NDUFA6, COX6A1, COX6C, NDUFB2 |